However, bone metastasis was not a prognostic factor affecting CSS in patients with HR+/HER2- (χ2=0.085, P=0.770) or HR+/HER2+ (χ2=1.82, P=0.177) (Supplementary Figure S1 and Table 4). The gene discussed is ERBB2; the disease is bone metastasis.